Summit shares descend as PD-1/VEGF asset misses early survival mark
BioSpace
Summit Therapeutics planned an early interim progression-free survival readout for HARMONi-3 in the hope of enabling earlier regulatory engagement--but the early analysis delivered disappointment for t
pharminent
May 4, 2026 (Last updated: May 4, 2026)
BioSpace
Summit Therapeutics planned an early interim progression-free survival readout for HARMONi-3 in the hope of enabling earlier regulatory engagement–but the early analysis delivered disappointment for t
